常见药物与卵巢癌生存:系统综述与荟萃分析
该研究通过四项系统综述评估二甲双胍、他汀类、β受体阻滞剂、阿司匹林及非阿司匹林非甾体抗炎药与卵巢癌生存的关联。共纳入36项研究,排除潜在永恒时间偏倚后荟萃分析显示他汀类使用者生存改善(pHR 0.76,95%CI 0.68-0.85),其他药物无总体生存获益。
要点
- 他汀类使用与卵巢癌生存改善相关(pHR 0.76,95%CI 0.68-0.85)
- 二甲双胍、β受体阻滞剂、阿司匹林及NA-NSAIDs无总体生存获益
- 围手术期β受体阻滞剂使用可能改善生存,但证据有限
核心结论
- 他汀类使用与更好的卵巢癌生存相关,但仍需进一步研究 preferably 临床试验。
- 关于二甲双胍、β受体阻滞剂、阿司匹林及NA-NSAIDs的数据不足以得出结论。
研究设计与样本
- 四项系统综述与荟萃分析,共纳入36项研究(二甲双胍8项、他汀类12项、β受体阻滞剂11项、阿司匹林和/或NA-NSAIDs 9项),评估偏倚风险。
主要发现
- 排除潜在永恒时间偏倚后,他汀类使用者相比非使用者生存改善(pHR 0.76,95%CI 0.68-0.85)。
- 二甲双胍、β受体阻滞剂、阿司匹林或NA-NSAIDs使用与总体生存获益无关。
- 两项研究的合并结果提示围手术期β受体阻滞剂使用可能与生存改善相关。
- 存在潜在永恒时间偏倚的研究更可能报告这些药物与生存获益相关。
关键数值与推荐
- 他汀类使用者 vs 非使用者:pHR 0.76(95%CI 0.68-0.85),基于无永恒时间偏倚研究。
- 二甲双胍、β受体阻滞剂、阿司匹林、NA-NSAIDs:无总体生存获益(未报告具体数值)。
临床怎么用
- 他汀类使用可能与卵巢癌生存改善相关,但尚无足够证据推荐用于改善生存。
- 其他常见慢性病药物(二甲双胍、β受体阻滞剂、阿司匹林、NA-NSAIDs)不推荐用于改善卵巢癌生存。
局限性
- 研究间存在异质性,永恒时间偏倚是主要偏倚来源。
- 他汀类的关联需临床试验进一步验证。
- 二甲双胍、β受体阻滞剂、阿司匹林及NA-NSAIDs的数据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Ovarian cancer is usually diagnosed at an advanced stage when five-year relative survival is <50%. Therefore, strategies to improve survival are required. Studies suggest associations between common chronic disease medications such as metformin, statins, beta-blockers, aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NA-NSAIDs) and improved cancer survival. We aimed to review the evidence for a possible relation between these medications and survival among women with ovarian cancer. METHODS: We conducted four systematic reviews and evaluated the risk of bias in the included studies. Where possible, we calculated pooled hazard ratios (pHR) and 95% confidence intervals (CI), excluding studies considered to have the potential for immortal time bias (ITB) which, in practice, was the major source of bias. RESULTS: We identified 36 studies evaluating one or more of the medications (metformin n = 8, statins n = 12, beta-blockers n = 11, aspirin and/or NA-NSAIDs n = 9). We rated 21 studies as ITB-free. The meta-analysis of the ITB-free studies suggested improved survival in statin users compared to non-users (pHR: 0.76, 95%CI: 0.68-0.85), but no overall survival benefit associated with use of metformin, beta-blockers, aspirin or NA-NSAIDs. The pooled result of two studies did, however, suggest a possible association between perioperative beta-blocker use and improved survival. Studies considered to have potential ITB were more likely to report survival benefits associated with these medications. CONCLUSION: Statin use is associated with better ovarian cancer survival but further study, preferably a clinical trial, is required. There are insufficient data to draw conclusions regarding metformin, beta-blockers, aspirin and NA-NSAIDs.
引用
- Majidi A, Na R, Dixon-Suen S, et al. Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 2020. PMID: 32317171. doi:10.1016/j.ygyno.2020.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。